Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inavolisib plus palbociclib and fulvestrant versus placebo plus palbociclib and fulvestrant in PIK3CA-mutant HR+/HER2-negative advanced breast cancer
2023-505812-39-00Phase 3Authorised
- Sponsor
- Roche
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 27
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Inavolisib + palbociclib + fulvestrant with Placebo + palbociclib + fulvestrant (2 arms). Primary endpoint: Progression-free survival. Planned start Jul 2024; status: authorised.
02
Drugs
inavolisib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2023-505812-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505812-39-00.